Anti-CD38 monoclonal antibodies represent an important advance in the treatment of multiple myeloma, providing new effective options for patients with newly diagnosed and relapsed/refractory disease.
Role of CD38 Antibodies in Multiple Myeloma
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
